Search

Displaying results 2171 - 2180 of 4345 in total
  1. Drug

    Tannic acid

    go.drugbank.com/drugs/DB09372
    ApprovedInvestigational

    Tannic acid is also taken by mouth and applied directly for bleeding, chronic diarrhea, dysentery, bloody urine, painful joints, persistent coughs, and cancer. … Tannic acid is found in the nutgalls formed by insects on twigs of certain oak trees (Quercus infectoria and other Quercus species). It is removed and used as medicine.

  2. Drug

    Fondaparinux

    go.drugbank.com/drugs/DB00569
    ApprovedInvestigational

    Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold.

    Products: ARIXTRA ® 10MG /0.8 ML
  3. Drug

    Interferon beta-1a

    go.drugbank.com/drugs/DB00060
    ApprovedInvestigational

    It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced.

  4. Drug

    Mometasone furoate

    go.drugbank.com/drugs/DB14512
    ApprovedInvestigationalVet approved

    Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label] . It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and highe...

  5. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab.

    Products: Darzalex 20mg/mL Concentrate for Solution for Infusion
  6. Drug

    Poloxamer 188

    go.drugbank.com/drugs/DB11333
    Approved

    P188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217].

  7. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. … APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation.

  8. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.

  9. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group.

    Mixtures: Bupap, Bupap
  10. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    [A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial.

    Products: REMLEAS™ hard capsules 40mg